| 產(chǎn)品編號 | bs-0481R |
| 英文名稱 | Rabbit Anti-IFN gamma antibody |
| 中文名稱 | 干擾素-γ/IFN-γ抗體 |
| 別 名 | IFNG; IFG; IFI; IFN Gamma; IFN Immune; IFN-gamma; IFNG; IFNG_HUMAN; Immune Interferon; Interferon gamma; Interferon Gamma Precursor; Macrophage Activating Factor; MAF; T Cell Interferon; Type II Interferon. |
 |
Specific References (11) | bs-0481R has been referenced in 11 publications.
|
| 研究領(lǐng)域 | 腫瘤 免疫學 信號轉(zhuǎn)導 干擾素 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 15kDa |
| 檢測分子量 | 20, 25 |
| 細胞定位 | 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human IFN Gamma: 81-166/166 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Mammalian Interferon gamma is mainly produced by T lymphocytes and NK cells. It is a pleiotropic cytokine involved in the regulation of nearly all phases of immune and inflammatory responses,including the activation, growth and differentiation of T cell, B cells, macrophages, NK cells and other cell types such as endothelial cells and fibroblasts. It has weak antiviral and antiproliferative activity, and poteniates the antiviral and anti tumor effects of IFN alpha / beta (type I interferon). It is upregulated by IL2, FGF basic, EGF and downregulated by vitamin D3 or DMN. Labile at pH 2. Function: Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. Subunit: Homodimer. Subcellular Location: Secreted. Tissue Specificity: Released primarily from activated T lymphocytes. Post-translational modifications: Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161. DISEASE: In Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis. Similarity: Belongs to the type II (or gamma) interferon family. SWISS: P01579 Gene ID: 3458 Database links: Entrez Gene: 3458 Human Entrez Gene: 15978 Mouse Omim: 147570 Human SwissProt: P01579 Human SwissProt: P01580 Mouse Unigene: 856 Human Unigene: 240327 Mouse
|
| 產(chǎn)品圖片 |
Sample:
HL-60 Cell (Human) Lysate at 40 ug
Primary: Anti- IFN gamma (bs-0481R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 15 kD
Observed band size: 16 kD
Sample:
Molt-4 Cell (Human) Lysate at 40 ug
Primary: Anti- IFN gamma (bs-0481R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 15 kD
Observed band size: 16 kD
Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-IFN gamma Polyclonal Antibody, Unconjugated(bs-0481R) 1:500, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
